Cargando…
Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
Background: Phase-III ASPECCT and randomised phase-II WJOG6510G trials demonstrated the noninferiority of panitumumab, when compared with cetuximab, for overall survival in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. Methods: The subgroup that received b...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407286/ https://www.ncbi.nlm.nih.gov/pubmed/32605298 http://dx.doi.org/10.3390/cancers12071715 |
_version_ | 1783567592215019520 |
---|---|
author | Taniguchi, Hiroya Yamanaka, Takeharu Sakai, Daisuke Muro, Kei Yamazaki, Kentaro Nakata, Susumu Kimura, Hiroyuki Ruff, Paul Kim, Tae Won Peeters, Marc Price, Timothy |
author_facet | Taniguchi, Hiroya Yamanaka, Takeharu Sakai, Daisuke Muro, Kei Yamazaki, Kentaro Nakata, Susumu Kimura, Hiroyuki Ruff, Paul Kim, Tae Won Peeters, Marc Price, Timothy |
author_sort | Taniguchi, Hiroya |
collection | PubMed |
description | Background: Phase-III ASPECCT and randomised phase-II WJOG6510G trials demonstrated the noninferiority of panitumumab, when compared with cetuximab, for overall survival in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. Methods: The subgroup that received bevacizumab either prior to panitumumab or cetuximab monotherapy (ASPECCT) or in combination with irinotecan (WJOG6510G) was included. Multivariate Cox models were created, including the treatment arms as covariates together with patient, disease and treatment characteristics. Results: We included 185 and 189 patients in the panitumumab and cetuximab arms, respectively. The median overall survival was 12.8 and 10.1 months [p = 0.0031; log-rank test, stratified by trial; hazard ratio (HR), 0.72; 95% confidence interval (CI), 0.58–0.90], and the median progression-free survival was 4.7 and 4.1 months, in the panitumumab and cetuximab arms, respectively (p = 0.0207; HR, 0.79; 95% CI, 0.64–0.97). The treatment regimen was an independent prognostic factor of overall survival (adjusted HR, 0.69; 95% CI, 0.54–0.87; p = 0.0013). Conclusions: Panitumumab significantly prolonged the overall survival and progression-free survival, when compared with cetuximab in the cohort that previously received bevacizumab in the included studies. Clinical Trial Registration: ASPECCT trial registered with ClinicalTrials.gov (NCT01001377) and WJOG6510G trial registered with UMIN-CTR (UMIN000006643). |
format | Online Article Text |
id | pubmed-7407286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74072862020-08-11 Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G Taniguchi, Hiroya Yamanaka, Takeharu Sakai, Daisuke Muro, Kei Yamazaki, Kentaro Nakata, Susumu Kimura, Hiroyuki Ruff, Paul Kim, Tae Won Peeters, Marc Price, Timothy Cancers (Basel) Article Background: Phase-III ASPECCT and randomised phase-II WJOG6510G trials demonstrated the noninferiority of panitumumab, when compared with cetuximab, for overall survival in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. Methods: The subgroup that received bevacizumab either prior to panitumumab or cetuximab monotherapy (ASPECCT) or in combination with irinotecan (WJOG6510G) was included. Multivariate Cox models were created, including the treatment arms as covariates together with patient, disease and treatment characteristics. Results: We included 185 and 189 patients in the panitumumab and cetuximab arms, respectively. The median overall survival was 12.8 and 10.1 months [p = 0.0031; log-rank test, stratified by trial; hazard ratio (HR), 0.72; 95% confidence interval (CI), 0.58–0.90], and the median progression-free survival was 4.7 and 4.1 months, in the panitumumab and cetuximab arms, respectively (p = 0.0207; HR, 0.79; 95% CI, 0.64–0.97). The treatment regimen was an independent prognostic factor of overall survival (adjusted HR, 0.69; 95% CI, 0.54–0.87; p = 0.0013). Conclusions: Panitumumab significantly prolonged the overall survival and progression-free survival, when compared with cetuximab in the cohort that previously received bevacizumab in the included studies. Clinical Trial Registration: ASPECCT trial registered with ClinicalTrials.gov (NCT01001377) and WJOG6510G trial registered with UMIN-CTR (UMIN000006643). MDPI 2020-06-28 /pmc/articles/PMC7407286/ /pubmed/32605298 http://dx.doi.org/10.3390/cancers12071715 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Taniguchi, Hiroya Yamanaka, Takeharu Sakai, Daisuke Muro, Kei Yamazaki, Kentaro Nakata, Susumu Kimura, Hiroyuki Ruff, Paul Kim, Tae Won Peeters, Marc Price, Timothy Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G |
title | Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G |
title_full | Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G |
title_fullStr | Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G |
title_full_unstemmed | Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G |
title_short | Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G |
title_sort | efficacy of panitumumab and cetuximab in patients with colorectal cancer previously treated with bevacizumab; a combined analysis of individual patient data from aspecct and wjog6510g |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407286/ https://www.ncbi.nlm.nih.gov/pubmed/32605298 http://dx.doi.org/10.3390/cancers12071715 |
work_keys_str_mv | AT taniguchihiroya efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g AT yamanakatakeharu efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g AT sakaidaisuke efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g AT murokei efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g AT yamazakikentaro efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g AT nakatasusumu efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g AT kimurahiroyuki efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g AT ruffpaul efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g AT kimtaewon efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g AT peetersmarc efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g AT pricetimothy efficacyofpanitumumabandcetuximabinpatientswithcolorectalcancerpreviouslytreatedwithbevacizumabacombinedanalysisofindividualpatientdatafromaspecctandwjog6510g |